Mark David Orland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark David Orland has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Carmelo Gurnari
Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
3 shared publications Arda Durmaz
Department of Translational Hematology and Oncology Research Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA
2 shared publications- Carlos Bravo-Perez
Department of Translational Hematology and Oncology Research Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA
2 shared publications - Jaroslaw P. Maciejewski
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
2 shared publications - Luca Guarnera
Department of Translational Hematology and Oncology Research Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA
2 shared publications - Stephan Hutter
MLL Munich Leukemia Laboratory Munich Germany
2 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Wiley in American Journal of Hematology
Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure
BCOR and BCORL1 (BCOR/L1 ) mutations are observed in both myeloid neoplasms (MN) and bone marrow failure syndromes (BMF), but their clinical significance may differ. We analyzed 11 340 patients and identified 418 BCOR/L1 ‐mutated patients, focusing on differences between MN and BMF. Compared with MN, BMF was associated with younger age, a higher frequency of normal karyotype, a greater proportion of missense mutations, and significantly lower variant allele frequencies (VAFs). We next compared BCOR/L1 ‐mutated cases with wild‐type cases. In MN, BCOR/L1 mutations were associated with older age, inferior survival, and a higher number of co‐occurring mutations, whereas in BMF, they were associated with a higher prevalence of PNH clones. Single‐cell DNA sequencing and VAF‐based analysis demonstrated that BCOR/L1 mutations were usually secondary in MN but primary events in BMF. Longitudinal sequencing revealed that BCOR/L1 ‐mutant clones often contracted or disappeared over time, even in progression, suggesting limited clonal fitness of BCOR/L1 mutations themselves; instead, progression was associated with increased mutational burden, particularly in RUNX1 . Prognostically, BCOR/L1 mutations were associated with inferior survival in MN, whereas in BMF they were not associated with prognosis and tended to correlate with a favorable response to immunosuppressive therapy. RNA‐sequencing analyses showed reduced BCOR/L1 expression in BMF, and BCOR knockout was associated with reduced HLA class I expression. Our findings suggest that BCOR/L1 mutations are secondary events in MN and co‐occurring mutations may influence disease progression and prognosis, whereas in BMF they appear to be ancestral events acquired independently of progression to MN, potentially through immune privilege‐related mechanisms.
- 7 November 2026
- Published by Wiley in American Journal of Hematology
Open AccessDistinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure
BCOR and BCORL1 (BCOR/L1 ) mutations are observed in both myeloid neoplasms (MN) and bone marrow failure syndromes (BMF), but their clinical significance may differ. We analyzed 11 340 patients and identified 418 BCOR/L1 ‐mutated patients, focusing on differences between MN and BMF. Compared with MN, BMF was associated with younger age, a higher frequency of normal karyotype, a greater proportion of missense mutations, and significantly lower variant allele frequencies (VAFs). We next compared BCOR/L1 ‐mutated cases with wild‐type cases. In MN, BCOR/L1 mutations were associated with older age, inferior survival, and a higher number of co‐occurring mutations, whereas in BMF, they were associated with a higher prevalence of PNH clones. Single‐cell DNA sequencing and VAF‐based analysis demonstrated that BCOR/L1 mutations were usually secondary in MN but primary events in BMF. Longitudinal sequencing revealed that BCOR/L1 ‐mutant clones often contracted or disappeared over time, even in progression, suggesting limited clonal fitness of BCOR/L1 mutations themselves; instead, progression was associated with increased mutational burden, particularly in RUNX1 . Prognostically, BCOR/L1 mutations were associated with inferior survival in MN, whereas in BMF they were not associated with prognosis and tended to correlate with a favorable response to immunosuppressive therapy. RNA‐sequencing analyses showed reduced BCOR/L1 expression in BMF, and BCOR knockout was associated with reduced HLA class I expression. Our findings suggest that BCOR/L1 mutations are secondary events in MN and co‐occurring mutations may influence disease progression and prognosis, whereas in BMF they appear to be ancestral events acquired independently of progression to MN, potentially through immune privilege‐related mechanisms.
- Open Access
- 8 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (2) , 197-208
Telomere content and genomics of myeloid neoplasia by whole-genome sequencing
Telomere length shortening has been associated with genomic instability and acquisition of molecular lesions, but these processes have not been systematically studied across large cohorts of myeloid neoplasia (MN). As proof of concept for a novel, cross-validated whole-genome sequencing–based method of telomere content (TC) determination combined with mutations, transcriptomics, and functional assays, we studied TC in correlation with specific molecular features of a large cohort (N = 1804) of patients with MN, including acute myeloid leukemia (AML) and myelodysplastic syndrome. When compared with healthy participants and patients with nonclonal diseases such as persistent polyclonal B-cell lymphocytosis, both MN and nonmalignant controls with clonal disease, such as paroxysmal nocturnal hemoglobinuria and aplastic anemia, exhibited decreased TC. Furthermore, we show that TC is lowered in adult MN abrogating correlation with age with considerable TC diversification among certain morphologic and molecular subtypes. For instance, AML harbored the lowest TC. Furthermore, MN originating from a more mature cell of origin (eg, acute promyelocytic leukemia) or characterized by hyperproliferative driver mutations (eg, RAS pathway genes) had lower TC, possibly indicating a loss of telomere maintenance capacity. In contrast, compared with other mutations, MN subtypes arising in a context of profound genetic alterations, such as TP53 mutations and complex karyotype, exhibited a relatively higher/preserved TC. This phenomenon did not involve alternative lengthening processes but was rather consistent with an increased TC due to preserved activity of the telomerase complex. Our results describe a common and genotype-specific telomeric makeup of a large cohort of patients with MN providing a molecular benchmark for future therapeutic targeting of the telomere machinery.
- 8 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (2) , 197-208
Open AccessTelomere content and genomics of myeloid neoplasia by whole-genome sequencing
Telomere length shortening has been associated with genomic instability and acquisition of molecular lesions, but these processes have not been systematically studied across large cohorts of myeloid neoplasia (MN). As proof of concept for a novel, cross-validated whole-genome sequencing–based method of telomere content (TC) determination combined with mutations, transcriptomics, and functional assays, we studied TC in correlation with specific molecular features of a large cohort (N = 1804) of patients with MN, including acute myeloid leukemia (AML) and myelodysplastic syndrome. When compared with healthy participants and patients with nonclonal diseases such as persistent polyclonal B-cell lymphocytosis, both MN and nonmalignant controls with clonal disease, such as paroxysmal nocturnal hemoglobinuria and aplastic anemia, exhibited decreased TC. Furthermore, we show that TC is lowered in adult MN abrogating correlation with age with considerable TC diversification among certain morphologic and molecular subtypes. For instance, AML harbored the lowest TC. Furthermore, MN originating from a more mature cell of origin (eg, acute promyelocytic leukemia) or characterized by hyperproliferative driver mutations (eg, RAS pathway genes) had lower TC, possibly indicating a loss of telomere maintenance capacity. In contrast, compared with other mutations, MN subtypes arising in a context of profound genetic alterations, such as TP53 mutations and complex karyotype, exhibited a relatively higher/preserved TC. This phenomenon did not involve alternative lengthening processes but was rather consistent with an increased TC due to preserved activity of the telomerase complex. Our results describe a common and genotype-specific telomeric makeup of a large cohort of patients with MN providing a molecular benchmark for future therapeutic targeting of the telomere machinery.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (12) , 1588-1595
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges
Despite significant progress and improving outcomes in the management of head and neck squamous cell carcinoma (HNSCC), there are few effective treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma. The advent of immune checkpoint inhibitors has changed the treatment algorithm of head and neck squamous cell carcinoma and are approved in the frontline setting for recurrent and metastatic (R/M) head and neck squamous cell carcinomas. Although promising for some patients, most patients with R/M HNSCC do not derive clinical benefit from currently approved checkpoint inhibitors. Many studies are underway to identify the patient population that would benefit the most from immunotherapy as well as postimmunotherapy treatment failures, including novel combinations of immunomodulatory therapies. In this review, we summarize the clinical development of all major clinical trials of immunotherapy in HNSCC.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (12) , 1588-1595
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges
Despite significant progress and improving outcomes in the management of head and neck squamous cell carcinoma (HNSCC), there are few effective treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma. The advent of immune checkpoint inhibitors has changed the treatment algorithm of head and neck squamous cell carcinoma and are approved in the frontline setting for recurrent and metastatic (R/M) head and neck squamous cell carcinomas. Although promising for some patients, most patients with R/M HNSCC do not derive clinical benefit from currently approved checkpoint inhibitors. Many studies are underway to identify the patient population that would benefit the most from immunotherapy as well as postimmunotherapy treatment failures, including novel combinations of immunomodulatory therapies. In this review, we summarize the clinical development of all major clinical trials of immunotherapy in HNSCC.
- Open Access
- 12 June 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3058-3062
Thrombocytosis and megakaryocyte changes associated with PRCA
Joelle Abdallah, Robert George Williams, Hussein Awada, Ganesh Raman, Yusuf M Ozcan, Mark David Orland, Mutlu Mete, Weina Chen, Carmelo Gurnari, Jaroslaw P Joelle Abdallah, Robert George Williams, Hussein Awada, Ganesh Raman, Yusuf M Ozcan, Mark David Orland, Mutlu Mete, Weina Chen, Carmelo Gurnari, Jaroslaw P
- 12 June 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3058-3062
Open AccessThrombocytosis and megakaryocyte changes associated with PRCA
Joelle Abdallah, Robert George Williams, Hussein Awada, Ganesh Raman, Yusuf M Ozcan, Mark David Orland, Mutlu Mete, Weina Chen, Carmelo Gurnari, Jaroslaw P Joelle Abdallah, Robert George Williams, Hussein Awada, Ganesh Raman, Yusuf M Ozcan, Mark David Orland, Mutlu Mete, Weina Chen, Carmelo Gurnari, Jaroslaw P
- Open Access
- 11 October 2021
- Published by Springer Nature in Research Square
Are Patients with Cardiovascular Disease at Higher Risk for Postoperative Complications following Total Hip or Total Knee Replacements? A Retrospective Cohort Study
Background: Cardiovascular disease affects 121.5 million Americans, or 48% of the adult US population and is the leading cause of death in the United States. The demand for total joint replacement is expected to increase due to an aging population and advances in technology. Given the prevalence of cardiovascular disease and the expected increase in total joint replacement procedures, we sought to examine whether cardiovascular disease was associated with increased postoperative complications in patients undergoing total hip and knee replacements.Methods:CPT codes were used to investigate the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database for patients who underwent total hip or knee replacements from 2010 to 2017. Patients were classified as having cardiovascular disease as per the American Health Association guidelines. Patient samples with all possible covariates were included in a multivariate logistic regression analysis. A patient sample size of 119,076 for total hip and 189,297 for total knee replacement was analyzed.Results: Patients with cardiovascular disease were found to have a statistically significant increased risk for the following postoperative complications: sepsis, wound complications, pneumonia, urinary tract infection, myocardial infarction, unplanned intubation, and cardiac arrest. Conclusions: Patients with cardiovascular disease undergoing a total hip or knee replacement have increased risk for wound, infectious and cardiovascular-associated postoperative complications. This finding necessitates the need for more frequent and sooner postoperative visits, a stringent cardiovascular preoperative evaluation, and patient education on the increased postoperative risks of joint replacements to lower the incidence of complications.
- 11 October 2021
- Published by Springer Nature in Research Square
Open AccessAre Patients with Cardiovascular Disease at Higher Risk for Postoperative Complications following Total Hip or Total Knee Replacements? A Retrospective Cohort Study
Background: Cardiovascular disease affects 121.5 million Americans, or 48% of the adult US population and is the leading cause of death in the United States. The demand for total joint replacement is expected to increase due to an aging population and advances in technology. Given the prevalence of cardiovascular disease and the expected increase in total joint replacement procedures, we sought to examine whether cardiovascular disease was associated with increased postoperative complications in patients undergoing total hip and knee replacements.Methods:CPT codes were used to investigate the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database for patients who underwent total hip or knee replacements from 2010 to 2017. Patients were classified as having cardiovascular disease as per the American Health Association guidelines. Patient samples with all possible covariates were included in a multivariate logistic regression analysis. A patient sample size of 119,076 for total hip and 189,297 for total knee replacement was analyzed.Results: Patients with cardiovascular disease were found to have a statistically significant increased risk for the following postoperative complications: sepsis, wound complications, pneumonia, urinary tract infection, myocardial infarction, unplanned intubation, and cardiac arrest. Conclusions: Patients with cardiovascular disease undergoing a total hip or knee replacement have increased risk for wound, infectious and cardiovascular-associated postoperative complications. This finding necessitates the need for more frequent and sooner postoperative visits, a stringent cardiovascular preoperative evaluation, and patient education on the increased postoperative risks of joint replacements to lower the incidence of complications.
- Open Access
- 1 November 2020
- Published by Wolters Kluwer Health in JAAOS: Global Research and Reviews
- Vol. 4 (11) , e20.00043
Surgical Duration Implicated in Major Postoperative Complications in Total Hip and Total Knee Arthroplasty: A Retrospective Cohort Study
Ta from 2010 to 2017 from the American College of Surgeons National Surgical Quality Improvement Program database. Methods: The American College of Surgeons National Surgical Quality Improvement Program database was queried for patients undergoing total hip and knee arthroplasty by their respective Current Procedural Terminology codes. Operation time was stratified into four quartiles with equal sample sizes in each quartile for total hip and knee arthroplasty separately. The first quartile of surgical times was used as the control to which the other three quartiles were compared. Multivariate logistic regression analysis was performed on all samples that accounted for possible covariates, totaling 119,076 patients for total hip and 189,297 for total knee arthroplasty. Results: The third and fourth quartiles of total hip and total knee arthroplasty were markedly associated with higher incidences of wound complications, particularly infection and dehiscence. In addition, prolonged total hip arthroplasty was associated with a markedly higher rate of urinary tract infections for the third and fourth quartiles, and deep vein thrombosis in the fourth quartile. Conclusions: The surgical duration of total hip and knee arthroplasties is an independent risk factor for wound complications and several other important postoperative complications. Therefore, extensive preoperative planning and postoperative prophylactic measures should be performed to minimize patient morbidity and reduce hospital costs....
- 1 November 2020
- Published by Wolters Kluwer Health in JAAOS: Global Research and Reviews
- Vol. 4 (11) , e20.00043
Open AccessSurgical Duration Implicated in Major Postoperative Complications in Total Hip and Total Knee Arthroplasty: A Retrospective Cohort Study
Ta from 2010 to 2017 from the American College of Surgeons National Surgical Quality Improvement Program database. Methods: The American College of Surgeons National Surgical Quality Improvement Program database was queried for patients undergoing total hip and knee arthroplasty by their respective Current Procedural Terminology codes. Operation time was stratified into four quartiles with equal sample sizes in each quartile for total hip and knee arthroplasty separately. The first quartile of surgical times was used as the control to which the other three quartiles were compared. Multivariate logistic regression analysis was performed on all samples that accounted for possible covariates, totaling 119,076 patients for total hip and 189,297 for total knee arthroplasty. Results: The third and fourth quartiles of total hip and total knee arthroplasty were markedly associated with higher incidences of wound complications, particularly infection and dehiscence. In addition, prolonged total hip arthroplasty was associated with a markedly higher rate of urinary tract infections for the third and fourth quartiles, and deep vein thrombosis in the fourth quartile. Conclusions: The surgical duration of total hip and knee arthroplasties is an independent risk factor for wound complications and several other important postoperative complications. Therefore, extensive preoperative planning and postoperative prophylactic measures should be performed to minimize patient morbidity and reduce hospital costs....